Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 71 to 80 of 257 total matches.
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
TREATMENT — Nonsteroidal antiinflammatory
drugs (NSAIDs), combination oral
contraceptives ...
The FDA has approved elagolix (Orilissa – AbbVie),
an oral gonadotropin-releasing hormone (GnRH)
antagonist, for management of moderate to severe
pain associated with endometriosis.
Topiramate for Epilepsy
The Medical Letter on Drugs and Therapeutics • May 23, 1997 (Issue 1001)
has decreased serum concentrations of ethinyl estradiol, the estrogen component in most oral contraceptives (WE ...
Topiramate (Topamax - Ortho-McNeil) has been approved by the US Food and Drug Administration (FDA) for oral use as an adjunct to other drugs in adult patients with partial seizures. Since this diagnostic category includes the largest number of patients with refractory epilepsy, new drugs with antiepileptic activity are usually tried first for this indication. Topiramate (toe pyre' a mate) is a structurally unique agent chemically related to the D-enantiomer of fructose.
Modafinil for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Mar 26, 1999 (Issue 1049)
serum concentrations of other drugs metabolized by 3A4, including oral contraceptives.
A 50% decrease ...
Modafinil (Provigil), a benzhydryl sulfinylacetamide non-amphetamine stimulant that has been used in Europe since 1995, has now been approved by the FDA for treatment of excessive daytime sleepiness associated with narcolepsy.
Blue light (ClearLight) for Acne Vulgaris
The Medical Letter on Drugs and Therapeutics • Jun 23, 2003 (Issue 1159)
tetracyclines and erythromycin. Hormonal therapy has included oral contraceptives and spironolactone (Aldactone ...
A high-intensity, narrow-band blue light (ClearLight -Lumenis) approved by the FDA for treatment of moderate inflammatory acne vulgaris has been featured in some stories in fashion magazines. This review describes the etiology and treatment of acne, as well as the mechanism of action, clinical studies, adverse effects, dosage and cost of the drug.
Eslicarbazepine Acetate (Aptiom) for Epilepsy
The Medical Letter on Drugs and Therapeutics • May 26, 2014 (Issue 1443)
, such as simvastatin and
oral contraceptives.5,6
Enzyme-inducing antiepileptic drugs such as phenytoin ...
Eslicarbazepine acetate (Aptiom – Sunovion) has been
approved by the FDA for adjunctive treatment of partial-onset
seizures in adults. New drugs for epilepsy are
often approved by the FDA initially only as adjunctive
treatment for partial seizures. Eslicarbazepine acetate
is a prodrug of eslicarbazepine, which is the S-isomer of
the active metabolite of oxcarbazepine. Oxcarbazepine
itself is similar to carbamazepine. Both oxcarbazepine
and carbamazepine are available generically.
Tirzepatide (Zepbound) for Chronic Weight Management
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
contraceptives. The manufacturer recommends that
females with reproductive potential who are taking
an oral ...
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide, which was approved by
the FDA as Mounjaro for treatment of type 2 diabetes
in 2022, has now been approved as Zepbound (Lilly)
for chronic weight management in adults who have
a BMI ≥30 kg/m2 or a BMI ≥27 kg/m2 and at least
one weight-related comorbidity. The injectable
GLP-1 receptor agonists liraglutide (Saxenda) and
semaglutide (Wegovy) are approved for chronic
weight management in patients ≥12 years...
Med Lett Drugs Ther. 2023 Dec 25;65(1692):205-7 doi:10.58347/tml.2023.1692c | Show Introduction Hide Introduction
Itraconazole for Onychomycosis
The Medical Letter on Drugs and Therapeutics • Jan 19, 1996 (Issue 966)
contraceptives and increased neurotoxicity of vincristine (Oncovin, and others) have been reported in patients ...
Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.
Lumacaftor/Ivacaftor (Orkambi) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
. Lumacaftor/
ivacaftor may also decrease the efficacy of hormonal
contraceptives; use of a nonhormonal ...
The FDA has approved a fixed-dose combination
of lumacaftor and ivacaftor (Orkambi – Vertex) for
oral treatment of cystic fibrosis (CF) in patients
≥12 years old who are homozygous for the F508del
mutation. About 50% of patients in the US with
CF are homozygous for the F508del (also called
Phe508del) mutation. This is the first approved
indication for lumacaftor; ivacaftor is available
alone as Kalydeco for treatment of CF in patients
≥2 years old with other mutations. Orkambi is the
first drug to be approved in the US for treatment of
patients with the F508del...
Molnupiravir - An Oral Antiviral Drug for COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
should use effective contraception during treatment
with molnupiravir and for 4 days after the last dose ...
The investigational oral antiviral drug molnupiravir
(Merck/Ridgeback Biotherapeutics) was granted an
FDA Emergency Use Authorization (EUA) on December
23, 2021 for treatment of mild to moderate COVID-19
in outpatients ≥18 years old who are at high risk of
progressing to severe disease, including hospitalization
or death (see Table 1), and for whom alternative treatment options are
not available or clinically appropriate. Paxlovid (Pfizer),
nirmatrelvir copackaged with ritonavir, was granted
an EUA on December 22, 2021. The IV antiviral drug
remdesivir (Veklury) was approved by the...
Symfi, Symfi Lo, and Cimduo for HIV (online only)
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
;
alternatives should be considered for pregnant
women and those not using effective contraception.
Guidelines ...
The FDA has approved three new once-daily fixed-dose
antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the
non-nucleoside reverse transcriptase inhibitor (NNRTI)
efavirenz and the nucleoside reverse transcriptase
inhibitors (NRTIs) lamivudine and tenofovir disoproxil
fumarate (TDF) and were approved as complete
antiretroviral regimens. Symfi Lo contains a lower
dose of efavirenz than both Symfi and Atripla, a fixed-dose
combination of efavirenz, TDF, and the NRTI
emtricitabine that was approved in 2006. Cimduo
(Mylan), which...